While previous studies have identified risk factors such as low albumin and elevated creatinine levels, other studies have found no predictive factors, suggesting that pharmacogenetic investigations of melphalan metabolism may offer insights into individual predispositions to OM [18,20]. This evidence concerns the gene ALB and ocular melanoma.